恒瑞医药
(600276)
| 流通市值：4145.08亿 | | | 总市值：4312.85亿 |
| 流通股本：63.79亿 | | | 总股本：66.37亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 15,761,193,628.9 | 7,205,611,122.72 | 27,984,605,342.06 | 20,189,303,845.1 |
| 营业收入 | 15,761,193,628.9 | 7,205,611,122.72 | 27,984,605,342.06 | 20,189,303,845.1 |
| 二、营业总成本 | 10,900,173,954.42 | 5,134,690,588.2 | 21,008,000,532.03 | 15,089,979,241.8 |
| 营业成本 | 2,114,962,169.18 | 1,068,662,516.36 | 3,848,177,391.88 | 2,833,182,677.7 |
| 税金及附加 | 123,906,983.06 | 60,059,261.23 | 257,883,958.62 | 172,414,995.14 |
| 销售费用 | 4,389,305,497.87 | 1,967,222,708.33 | 8,336,069,025.76 | 6,109,287,761.42 |
| 管理费用 | 1,285,102,289.96 | 586,082,025.59 | 2,555,686,849.29 | 1,874,111,722.11 |
| 研发费用 | 3,227,933,482.1 | 1,533,207,293.28 | 6,582,915,544.87 | 4,548,870,345.14 |
| 财务费用 | -241,036,467.75 | -80,543,216.59 | -572,732,238.39 | -447,888,259.71 |
| 其中:利息费用 | 11,663,082.85 | 10,924,238.97 | 5,558,751.08 | 3,313,597.64 |
| 其中:利息收入 | 254,588,374.35 | 77,065,178.29 | 603,277,309.6 | 490,918,277.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 111,263,854.42 | -13,112,706.36 | 108,630,771.57 | 9,529,744.94 |
| 加:投资收益 | -22,157,896.9 | -6,818,455.69 | 4,279,363.56 | -31,420,370.48 |
| 资产处置收益 | 2,311,106.15 | 1,038,858.19 | 5,397,912.01 | 2,149,624.8 |
| 资产减值损失(新) | -9,443,508.19 | -1,395,839.13 | -32,538,341.38 | 9,250,184.59 |
| 信用减值损失(新) | 9,815,828.07 | 7,544,663.8 | 28,997,491.04 | -14,287,748.84 |
| 其他收益 | 206,083,607.18 | 27,803,856.33 | 399,259,997.05 | 270,744,490.42 |
| 四、营业利润 | 5,158,892,665.21 | 2,085,980,911.66 | 7,490,632,003.88 | 5,345,290,528.73 |
| 加:营业外收入 | 2,317,395.85 | 623,478.59 | 10,446,041.92 | 5,790,924.24 |
| 减:营业外支出 | 110,275,852.11 | 11,000,678.42 | 331,388,050.05 | 264,341,297.74 |
| 五、利润总额 | 5,050,934,208.95 | 2,075,603,711.83 | 7,169,689,995.75 | 5,086,740,155.23 |
| 减:所得税费用 | 596,263,551.74 | 199,161,750.51 | 832,695,348.22 | 470,409,977.77 |
| 六、净利润 | 4,454,670,657.21 | 1,876,441,961.32 | 6,336,994,647.53 | 4,616,330,177.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,454,670,657.21 | 1,876,441,961.32 | 6,336,994,647.53 | 4,616,330,177.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,450,106,384.46 | 1,874,055,519.98 | 6,336,527,014.75 | 4,619,575,874.29 |
| 少数股东损益 | 4,564,272.75 | 2,386,441.34 | 467,632.78 | -3,245,696.83 |
| 扣除非经常损益后的净利润 | 4,272,848,537.94 | 1,863,286,591.29 | 6,177,966,481.3 | 4,616,314,757.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.7 | 0.3 | 1 | 0.73 |
| (二)稀释每股收益 | 0.7 | 0.3 | 1 | 0.73 |
| 八、其他综合收益 | 26,151,612.62 | 2,346,805.44 | -624,026.11 | -12,630,993.15 |
| 归属于母公司股东的其他综合收益 | 26,443,986.59 | 2,446,707.84 | -2,352,161.55 | -11,499,309.03 |
| 九、综合收益总额 | 4,480,822,269.83 | 1,878,788,766.76 | 6,336,370,621.42 | 4,603,699,184.31 |
| 归属于母公司股东的综合收益总额 | 4,476,550,371.05 | 1,876,502,227.82 | 6,334,174,853.2 | 4,608,076,565.26 |
| 归属于少数股东的综合收益总额 | 4,271,898.78 | 2,286,538.94 | 2,195,768.22 | -4,377,380.95 |
| 公告日期 | 2025-08-21 | 2025-04-25 | 2025-03-31 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |